Pyc.asx

Looks you are already a member.

Driven to transform the lives of patients through a new generation of RNA therapeutics. PYC Therapeutics combines world-leading RNA therapeutic drug design with a revolutionary delivery technology based on a proprietary library of naturally derived Cell Penetrating Peptides CPPs to solve the delivery challenge associated with traditional RNA therapeutics. PYC has a initial focus on ophthalmology, neurodevelopmental and kidney diseases and aims to apply its platform technology to further indications. Our Platform is highly versatile and modular, offering broad potential across therapeutic areas. PYC's goal is to provide patients with no current treatment options a therapeutic that addresses the underlying cause of the disease. Truly Life-Changing Science.

Pyc.asx

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions. All rights reserved. ASX shareholders. Our Board. Corporate governance. Media centre. ASX rulebooks. ASX Compliance. ASX regulatory framework. Code of practice. Enter Keyword for Search. Trade our cash market. Trade our derivatives market. Clearing and settlement services.

New minor risk - Share price stability Jul

PYC Therapeutics Limited. PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of RNA therapeutics in Australia. About the company. It also focuses on the development of programs for kidney, neurodevelopmental, retinal, and central nervous system diseases. Revenue is forecast to grow Shareholders have been diluted in the past year.

PYC Therapeutics Limited. PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of RNA therapeutics in Australia. About the company. It also focuses on the development of programs for kidney, neurodevelopmental, retinal, and central nervous system diseases. Revenue is forecast to grow Shareholders have been diluted in the past year.

Pyc.asx

Financial Times Close. Search the FT Search. Show more World link World. Show more US link US. Show more Companies link Companies. Show more Tech link Tech. Show more Markets link Markets. Show more Opinion link Opinion. Show more Personal Finance link Personal Finance.

Cookies for cooties

Password is required. Updating information Please wait Macquarie Capital Alliance Limited. Please log in with your existing credentials. Cancel Continue. No thanks. Compare our membership packages. Search the FT Search. PYC's goal is to provide patients with no current treatment options a therapeutic that addresses the underlying cause of the disease. Sign up. Didn't get the code?

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions. All rights reserved.

Intelligent Investor Membership. Past Performance. PYC Therapeutics Limited. Territory Iron Limited. Verification code is required. Stay Connected. Is PYC's price volatile compared to industry and market? Add to Your Watchlists New watchlist. The code you entered is incorrect. New major risk - Financial position Nov Please choose another Invalid password: must not contain more than 3 consecutive identical characters Invalid password: must not contain more than 3 consecutive sequential characters The password cannot contain the user name, given name, or family name. Use our equities screener to discover other potential opportunities. Apply to become a participant. All markets data located on FT. Papyrus Australia.